We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

This study has been terminated.
(Poor enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00869518
First Posted: March 26, 2009
Last Update Posted: May 14, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of California, San Francisco
Results First Submitted: March 13, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Conditions: Staphylococcus Aureus
HIV Infections
Interventions: Drug: rifabutin plus trimethoprim sulfamethoxazole
Drug: placebo plus trimethoprim-sulfamethoxazole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rifabutin

Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole

rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days

Placebo

Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole

placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days


Participant Flow:   Overall Study
    Rifabutin   Placebo
STARTED   6   6 
COMPLETED   5   5 
NOT COMPLETED   1   1 
Lost to Follow-up                1                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rifabutin

Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole

rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days

Placebo

Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole

placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days

Total Total of all reporting groups

Baseline Measures
   Rifabutin   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 6   6   12 
Age 
[Units: Years]
Mean (Full Range)
 42.3 
 (25 to 49) 
 43.5 
 (25 to 63) 
 42.9 
 (25 to 63) 
Gender 
[Units: Participants]
     
Female   1   2   3 
Male   5   4   9 
Region of Enrollment 
[Units: Participants]
     
United States   6   6   12 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Eradication of S. Aureus Colonization   [ Time Frame: 30 days following completion of treatment ]

2.  Secondary:   Eradication of S. Aureus Colonization   [ Time Frame: 7 days following completion of treatment ]

3.  Secondary:   Eradication of S. Aureus Colonization   [ Time Frame: 60 days following completion of treatment ]

4.  Secondary:   Recurrent Skin and Skin Structure Infections (SSTI)   [ Time Frame: up to 30 days following completion of treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Brian S. Schwartz, MD
Organization: University of California, San Francisco
phone: 415-476-5767
e-mail: brian.schwartz@ucsf.edu



Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00869518     History of Changes
Other Study ID Numbers: 08033578
First Submitted: March 24, 2009
First Posted: March 26, 2009
Results First Submitted: March 13, 2014
Results First Posted: April 21, 2014
Last Update Posted: May 14, 2014